Fact Source: Financial Supervisory Service DART / 2025-02-12
Disclosure Type: Decision on Convening General Meeting of Shareholders
💡 3-Second Summary
SAMSUNG BIOLOGICS will hold its 14th Annual General Meeting of Shareholders on March 14 in Songdo, with critical agenda items dedicated to approving the FY2024 financial statements and electing prominent finance and policy heavyweights to its Board of Directors.
📊 1. [Key Disclosure Content & Major Figures Summary]
- Type of General Meeting: 14th Annual General Meeting of Shareholders (AGM)
- Date, Time & Venue: March 14, 2025, at 09:00 AM KST / Room 113, 1st Floor, Songdo Convensia (123 Central-ro, Yeonsu-gu, Incheon)
- Board Resolution Date: February 12, 2025 (All 4 independent directors attended with zero absences)
- Major Agendas Scheduled:
- Agenda No. 1: Approval of the 14th Fiscal Year (2024.1.1~12.31) Financial Statements
- Agenda No. 2: Amendments to the Articles of Incorporation
- Agenda No. 3: Election of Directors (1 New Internal Director, 1 New Independent Director)
- Agenda No. 4: Election of Independent Director Lee Chang-woo as an Audit Committee Member (Re-election)
- Agenda No. 5: Election of Lee Ho-seung as an Audit Committee Member (New Nomination)
- Agenda No. 6: Approval of the Director Remuneration Limit
- Nominee Profiles & Structural Metrics (3-year terms each):
- Yoo Seung-ho (Internal Director Nominee): Current Head of Management Support Center (CFO) at SAMSUNG BIOLOGICS. Former Head of financial management groups and corporate strategy divisions at Samsung Electronics.
- Lee Ho-seung (Independent Director & Audit Committee Nominee): Former Chief of Staff to the President for Policy and former 1st Vice Minister of Economy and Finance.
- Lee Chang-woo (Audit Committee Nominee for Re-election): Professor Emeritus at Seoul National University Graduate School of Business and current Chairman of the Audit Committee at SAMSUNG BIOLOGICS.
📈 2. [Expert Insight: What This Disclosure Means for Investors]
This regulatory notice serves as a standard corporate calendar update outlining voting procedures, while providing global macro investors with vital qualitative indicators regarding upcoming governance transitions. Though separate financial sheets are omitted in this specific filing, it establishes the administrative timeline to ratify the firm’s successful FY2024 top-line performance under Agenda No. 1.
The primary structural takeaway lies in the strategic composition of the board nominees. Elevating Yoo Seung-ho, a veteran corporate auditor with deep institutional experience inside Samsung Electronics’ core management support networks, highlights an intent to optimize multi-billion dollar capital expenditure (CAPEX) allocations as facility rollouts pick up speed.
Simultaneously, recruiting Lee Ho-seung—a premier technocrat who commanded macro policy for the state—provides the corporation with heavy policy insulation. His background is tailored to buffer geopolitical trade friction and streamline operational compliance as international barriers like the U.S. Biosecure Act redefine global supply networks.
Retaining a respected accounting scholar like Professor Lee Chang-woo alongside a former fiscal vice-minister directly solidifies internal controls, lowering risk premiums demanded by international asset managers. While the scheduling remains subject to minor operational adjustments, the unanimous board support implies a highly stable transition with near-certain passage of all proposed items on March 14.
📝 Editor’s Comment (by K-STOCK Editor)
SAMSUNG BIOLOGICS is putting together an incredibly heavy-hitting boardroom lineup ahead of its March shareholder meeting. The professional profiles being injected into the inner circle carry significant structural weight. Moving CFO Yoo Seung-ho into an official internal director chair reinforces cash-flow governance, while locking in former macroeconomic commander Lee Ho-seung as an independent director and audit member brings major public-sector foresight.
In the highly competitive international CDMO landscape, scaling up capacity is only half the battle; navigating complex international sanctions, biosecurity mandates, and trade policies is where long-term market dominance is secured. Re-anchoring their audit oversight with a mix of academic accounting authority and regulatory muscle is an ultimate defensive play that satisfies the strict ESG compliance checklist utilized by tier-one global funds, making this calendar disclosure a quiet but reassuring win for long-term holders.
📢 Disclaimer and Source Information
Source: This content was newly structured and written based on official data submitted to the Financial Supervisory Service’s Electronic Disclosure System (DART).
Investment Risk Notice: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
